Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib in Antihistamine-Resistant Chronic Spontaneous Urticaria
NCT04827589Phase 2Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Jul 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tirabrutinib in chronic spontaneous urticaria (CSU), sponsored by Gilead Sciences. Planned start Jul 2021; status: withdrawn.
02
Drugs
tirabrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04827589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827589.